LU92717I2 - Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable - Google Patents

Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable Download PDF

Info

Publication number
LU92717I2
LU92717I2 LU92717C LU92717C LU92717I2 LU 92717 I2 LU92717 I2 LU 92717I2 LU 92717 C LU92717 C LU 92717C LU 92717 C LU92717 C LU 92717C LU 92717 I2 LU92717 I2 LU 92717I2
Authority
LU
Luxembourg
Prior art keywords
eliglustat
possibly
acceptable salt
physiologically acceptable
disclosed
Prior art date
Application number
LU92717C
Other languages
English (en)
Original Assignee
Genzyme Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92717(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Michigan filed Critical Genzyme Corp
Publication of LU92717I2 publication Critical patent/LU92717I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU92717C 2001-07-16 2015-05-13 Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable LU92717I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16

Publications (1)

Publication Number Publication Date
LU92717I2 true LU92717I2 (fr) 2015-11-24

Family

ID=23182463

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92717C LU92717I2 (fr) 2001-07-16 2015-05-13 Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable

Country Status (16)

Country Link
US (11) US6855830B2 (fr)
EP (3) EP2067775B1 (fr)
JP (6) JP5038582B2 (fr)
AT (2) ATE554082T1 (fr)
BE (1) BE2015C029I2 (fr)
BR (3) BRPI0211379B8 (fr)
CA (1) CA2453978C (fr)
CY (1) CY2015028I2 (fr)
DK (3) DK1409467T3 (fr)
ES (3) ES2395122T3 (fr)
FR (1) FR15C0036I2 (fr)
HK (2) HK1132267A1 (fr)
IL (3) IL159905A0 (fr)
LU (1) LU92717I2 (fr)
PT (3) PT2266968E (fr)
WO (1) WO2003008399A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384719A1 (fr) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibiteurs de l'enzyme synthetase de glucosyl-ceramide pour soigner le cancer, la sphingolipidose et les infections microbiennes
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2002062777A2 (fr) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Composes du type amino-ceramide et procedes therapeutiques d'utilisation
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5038582B2 (ja) 2001-07-16 2012-10-03 ジェンザイム・コーポレーション Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
WO2003045928A1 (fr) * 2001-11-26 2003-06-05 Genzyme Corporation Synthese diastereoselective d'udp-glucose : inhibiteurs de la n-acylsphingosine glucosyltransferase
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
WO2006053043A2 (fr) * 2004-11-10 2006-05-18 Genzyme Corporation Methodes de traitement du diabete sucre
EP1841756B1 (fr) 2005-01-26 2011-09-07 Allergan, Inc. Amides d'acide 3-heterocyclyl-3-hydroxy-2-amino-propionique et composes associes presentant une activite analgesique et/ou immunostimulante
WO2007134086A2 (fr) 2006-05-09 2007-11-22 Genzyme Corporation Méthodes pour traiter une maladie de foie adipeux
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
WO2008109285A1 (fr) 2007-03-06 2008-09-12 Allergan, Inc. Procédés de traitement de troubles cognitifs
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
ES2711075T3 (es) 2007-03-06 2019-04-30 Allergan Inc Compuestos para su uso en el tratamiento de trastornos cognitivos
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2167485B1 (fr) 2007-05-31 2015-09-30 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
CA2701649C (fr) 2007-10-05 2016-05-24 Genzyme Corporation Procede utilisant des derives de ceramide pour traiter des maladies polykystiques des reins
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
EP2320886B1 (fr) * 2008-07-28 2017-06-28 Genzyme Corporation Inhibition de synthase de glucosylcéramide pour le traitement du glomérulopathie avec collapsus, et d'un autre trouble glomérulaire
CA2738768C (fr) 2008-10-03 2017-10-31 Genzyme Corporation Inhibiteurs de glucosylceramide synthase de type 2-acylaminopropoanol
EP3608330B1 (fr) 2008-12-16 2022-11-09 Genzyme Corporation Intermédiaires synthétiques utiles dans la préparation des conjugués oliogosaccharide-protéine
PL3133070T3 (pl) * 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
CN102845091A (zh) 2010-04-16 2012-12-26 京瓷株式会社 无线通信系统、高功率基站、低功率基站及通信控制方法
KR20140037082A (ko) 2011-04-22 2014-03-26 겐자임 코포레이션 가속 가공으로 변형된 산 알파 글루코시다제
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (fr) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibiteurs de l'enzyme udp-glucose : n-acyl-sphingosine glucosyltransférase
CN105745206B (zh) 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
WO2015059679A1 (fr) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Procédé amélioré pour la préparation d'éliglustat
AU2014342593B2 (en) 2013-10-29 2019-02-14 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
ES2856898T3 (es) 2015-02-02 2021-09-28 Univ Michigan Regents Inhibidores de glucosilceramida sintasa y métodos terapéuticos que usan los mismos
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
WO2016166170A1 (fr) 2015-04-14 2016-10-20 Sandoz Ag Chlorhydrate d'éliglustat cristallin
WO2017068496A1 (fr) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Procédé amélioré pour la préparation d'éliglustat et de ses sels
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
WO2017178499A1 (fr) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibiteurs de dégradation des glucosylcéramides dans le traitement des maladies des neurones moteurs
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (fr) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
WO2018225085A1 (fr) 2017-06-05 2018-12-13 Cipla Limited Dispersions solides stables d'hémitartrate d'éliglustat
KR20200100697A (ko) 2017-12-15 2020-08-26 젠자임 코포레이션 고쉐병의 치료 방법
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
WO2020194138A1 (fr) * 2019-03-22 2020-10-01 Piramal Enterprises Limited Procédé amélioré pour la préparation d'éliglustat et de son intermédiaire
WO2020193746A1 (fr) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction de la survie de patients atteints de mélanome
EP4048397B1 (fr) 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Inhibiteurs de la glucosylcéramide synthase pour des applications thérapeutiques
WO2021214771A1 (fr) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Inhibiteurs de glucosylcéramide synthase pour la prévention et le traitement de maladies virales
WO2021221953A1 (fr) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Inhibiteurs pyridine de la glucosylcéramide synthase et procédés thérapeutiques les utilisant
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (fr) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Composés tirapazamine et quazinone à utiliser dans le traitement des gangliosidoses gm2

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
DE69426331T2 (de) 1993-08-13 2001-06-21 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
CA2182485A1 (fr) * 1994-02-02 1995-08-10 Yong Wei Composes et liposomes possedant des proprietes pharmaceutiques; methodesd'utilisation
EP0765865B1 (fr) * 1994-06-10 2001-12-12 Seikagaku Corporation Compose de 2-acylaminopropanol et composition medicinale
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (fr) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Composes de type amino ceramide et leurs methodes d'utilisation therapeutiques
WO2001004108A1 (fr) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Composes de type amino-ceramide et procedes therapeutiques d'utilisation
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
ATE358473T1 (de) * 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
EP1384719A1 (fr) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibiteurs de l'enzyme synthetase de glucosyl-ceramide pour soigner le cancer, la sphingolipidose et les infections microbiennes
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (fr) * 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Composes du type amino-ceramide et procedes therapeutiques d'utilisation
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP5038582B2 (ja) 2001-07-16 2012-10-03 ジェンザイム・コーポレーション Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
WO2007134086A2 (fr) * 2006-05-09 2007-11-22 Genzyme Corporation Méthodes pour traiter une maladie de foie adipeux

Also Published As

Publication number Publication date
JP2013136618A (ja) 2013-07-11
US7196205B2 (en) 2007-03-27
JP2005502635A (ja) 2005-01-27
JP5227348B2 (ja) 2013-07-03
US7763738B2 (en) 2010-07-27
DK2067775T3 (da) 2012-07-16
EP2266968A3 (fr) 2011-05-18
BR122015016313B1 (pt) 2019-04-16
JP4708073B2 (ja) 2011-06-22
BR122015016313B8 (pt) 2021-05-25
ES2395122T3 (es) 2013-02-08
ATE554082T1 (de) 2012-05-15
CY2015028I1 (el) 2016-07-27
BR122015016314B8 (pt) 2021-05-25
US20080058514A1 (en) 2008-03-06
WO2003008399A1 (fr) 2003-01-30
CY2015028I2 (el) 2016-07-27
BRPI0211379B1 (pt) 2018-02-14
ATE555102T1 (de) 2012-05-15
US6855830B2 (en) 2005-02-15
HK1132267A1 (en) 2010-02-19
US20050009872A1 (en) 2005-01-13
IL159905A (en) 2009-05-04
DK2266968T3 (da) 2013-04-08
US8138353B2 (en) 2012-03-20
ES2395463T3 (es) 2013-02-15
EP2067775A1 (fr) 2009-06-10
US8779163B2 (en) 2014-07-15
US7615573B2 (en) 2009-11-10
IL193244A0 (en) 2009-02-11
BRPI0211379B8 (pt) 2021-05-25
US20030050299A1 (en) 2003-03-13
FR15C0036I2 (fr) 2016-05-27
US20210171507A1 (en) 2021-06-10
EP2266968A2 (fr) 2010-12-29
JP2010095546A (ja) 2010-04-30
US9546161B2 (en) 2017-01-17
BR122015016314B1 (pt) 2019-04-16
PT1409467E (pt) 2012-10-24
JP5038582B2 (ja) 2012-10-03
JP2005255686A (ja) 2005-09-22
US20150148534A1 (en) 2015-05-28
PT2266968E (pt) 2013-02-25
CA2453978C (fr) 2011-10-11
HK1153733A1 (fr) 2012-04-05
EP2067775B1 (fr) 2012-04-25
US20050222244A1 (en) 2005-10-06
EP1409467A1 (fr) 2004-04-21
ES2399323T3 (es) 2013-03-27
US20110003987A1 (en) 2011-01-06
US20120296088A1 (en) 2012-11-22
BE2015C029I2 (fr) 2021-07-19
JP2017075151A (ja) 2017-04-20
JP2015180656A (ja) 2015-10-15
EP1409467B1 (fr) 2012-04-18
US7265228B2 (en) 2007-09-04
PT2067775E (pt) 2012-07-16
US20170334888A1 (en) 2017-11-23
US20190322649A1 (en) 2019-10-24
DK1409467T3 (da) 2012-07-16
JP6182254B2 (ja) 2017-08-16
BR0211379A (pt) 2004-08-17
CA2453978A1 (fr) 2003-01-30
IL159905A0 (en) 2004-06-20
FR15C0036I1 (fr) 2015-06-26
EP2266968B1 (fr) 2013-01-09
US20070203223A1 (en) 2007-08-30
ES2395463T4 (es) 2013-02-12

Similar Documents

Publication Publication Date Title
LU92717I2 (fr) Éliglustat, éventuellement sous la forme d'un sel physiologiquement acceptable
NL300815I2 (fr)
DK0923554T3 (da) N-Benzylpiperidin- og tetrahydropyridinderivater
EP1276480A4 (fr) Procede de fabrication d'enantiomeres de bupivacaine racemique, de compositions pharmaceutiques de bupivacaine, ces compositions pharmaceutiques de bupivacaine formulees sur sa base libre ou ses sels pharmaceutiquement acceptables et utilisation de ces compositions
HK1078580A1 (en) Antitumoral analogs of lamellarins
ATE294783T1 (de) Salze des 3-(2-(4-(4-(amino-imino-methyl)-phenyl)-4-methy -2,5-dioxo-imidazolidin-1-yl)- acetylamino)-3-phenyl-propionsäure-ethylesters
ITMI982857A0 (it) Processo per la sintesi di 5-(a-idrossialchil)benzo[1,3]diossoli
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
SE9701438D0 (sv) A new process
FI953994A0 (fi) Menetelmä (-)-N-metyyli-N-(4-(4-fenyyli-4-asetyyliaminopiperidiini-1-yl)-2-(3,4-diklorofenyyli)butyyli)bentsamidi ja sen farmaseuttisesti hyväksyttäviä suoloja
FR2699074B1 (fr) Procédé d'obtention d'un médicament se présentant sous la forme d'un produit comprimé pouvant être avalé, sucé, croqué, délité.
NO20030876D0 (no) Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin
HK1053791A1 (zh) 外消旋布比卡因對映體的製備方法，左旋布比卡因藥物組合物，自由碱基形式配方的左旋布比卡因藥物組合物或者其藥學上可接受的鹽以及自由碱基形式配方的左旋布比卡因藥物組合物的用途
ITTO990685A0 (it) Procedimento per la smaltatura a caldo dell'oro bianco.
ITVR20020007U1 (it) Capo d'abbigliamento, particolarmente per karting
BG106700A (en) Sodium 2-(4,6-dimethylpyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl) ethoxy-3,3-diphenylpropionate and use thereof as endothelin antagonist